所属类别： 20mg毫克/片 14片/盒
包装规格： 20mg毫克/片 14片/盒
生产厂家英文名：Japan Boehringer Ingelheim Pharmaceuticals
原产地英文商品名：Gilotrif tablets（ジオトリフ錠 20mg/Tablet 14Tablets/
中文参考商品译名：Gilotrif片（ジオトリフ錠）20mg毫克/片 14片/盒（7片*2板 PTP）
英文药名：Gilotrif Tablets（Afatinib Maleate）
它是易溶于水或二甲亚砜，难溶在甲醇中，微溶于乙醇（95）。分配系数登录P =4.7（PH9的或更多），日志D =3.8（pH7.4）
（Afatinib Maleate）New release of the world's first irreversible ErbB family inhibitor "Geotrif ® tablets" Based on the indications of EGFR gene mutation-positive inoperable or recurrent non-small cell lung cancerFirst dose of anticancer drug to be released from the tumor area pipeline of Boehringer IngelheimJapan Boehringer Ingelheim Co., Ltd. (Headquarters: Shinagawa-ku, Tokyo, President and CEO: Yoshiaki Aono, hereinafter "Nippon Boehringer Ingelheim") is an indication of the efficacy and effect of inoperable or recurrent nonsmall cell lung cancer positive for EGFR gene mutation, The oral anti-neoplastic agent/ tyrosine kinase inhibitor "Geotrif®tablet 20mg/30mg/40mg /same 50 mg" listed on the drug price on April 17th (hereinafter "Geotrif® tablet" generic name: afatinib maleic acid Salt) will be on sale from May 7th today.Lung cancer is the most deadly cancer in the world, and approximately 100,000 people are diagnosed as new lung cancer every year in Japan, and about 70,000 people died of lung cancer annually1. Of these, non-small cell lung cancer accounts for approximately 90% of cases of lung cancer.2, Geotrif® tablets bring new options for the treatment of nonsmall cell lung cancer and recurrent nonsmall cell lung cancer, which were previously considered as inoperable .Promotion of proper useNippon Boehringer Ingelheim will continue to promote proper use so that Geotrif®tablets are properly prescribed and administered to patients.Moreover, from the results of clinical trials so far, it is known that diarrhea and skin symptoms are expressed with high frequency as a side effect of Geotrif®. We will strive to provide information to healthcare professionals and patients and to promote sufficient understanding so that appropriate management can be taken against such side effects.About the outline of "Geotriff®tablets"Release date: May 7, 2014Drug Price Listing Date: April 17, 2014Approval date: January 17, 2014Product name: Geotrif ® tablet 20 mg / Geotrif ® tablet 30 mg / Geotrif ® tablet 40mg/Geotrif®tablet 50mgCommon name: afatinib maleateIndications/effects: EGFR gene mutation positive nonoperable or recurrent non small cell lung cancerDosage/administration: As an afaciniv for adults, usually 40 mg once daily is administered orally on an empty stomach. Although it may be increased or decreased according to the condition of the patient, it can be increased up to 50 mg once a day.About Geotrif®Geotrif® is the first irreversible ErbB family inhibitor in the world and covalently binds to the tyrosine kinase of the epidermal growth factor receptor (EGFR) and shows irreversible inhibitory action. Furthermore, against the tyrosine kinase of human epidermal growth factor receptor 2(HER2 (ErbB2)) and human epidermal growth factor receptor 4(ErbB4 (HER4)) belonging to the ErbB family as well as EGFR (ErbB1) It has been confirmed that sustained and selective inhibition of phosphorylation occurs.On the tumor area of ​​Boehringer IngelheimBased on outstanding scientific knowledge in the fields of respiratory diseases, cardiovascular diseases, metabolic diseases, central nervous system diseases, viral diseases, immune system diseases, Boehringer Ingelheim is an innovative anti-cancer We started a large-scale research program to develop drugs. Boehringer Ingelheim is working on the research and development of novel anticancer drugs in close collaboration with international scientific associations and multiple authoritative cancer research institutes globally.While aided by progress in science, we aim to develop a wide range of targeted therapies for various types of solid cancers and blood cancers. The tumor area pipeline of Boehringer Ingelheim continues to develop and this pipeline shows Boehringer Ingelheim's ongoing commitment to the development of the tumor area.